Life Summary
Jin Yang-gon is the chairman of HLB Group.

As he focuses on mid- to long-term growth strategies, he has stepped down from the CEO position and now serves only as chairman of the board of directors of the group’s listed affiliates, including HLB.

He is working to secure new growth engines through the commercialization of new drugs, including the anticancer drug “Rivoceranib,” as well as through mergers and acquisitions.

He was born on January 14, 1966, in Busan.

He graduated from the Department of Law at Wonkwang University and earned a master’s degree in business administration from Yonsei University Graduate School.

After working at Busan Bank and Peace Bank, he resigned and operated a pub.

In 1998, he founded the consulting firm JNR Partners.

In 2004, he established the investment company Golden Light and entered the field of corporate mergers and acquisitions, and began the bio business by acquiring HLB.

He has applied to the U.S. Food and Drug Administration (FDA) for approval of Rivoceranib as a treatment for liver cancer and is preparing for its commercialization.

He advocates people-centered management.

#JinYang-gon #HLB #HLBGroup #biotechnology #anticancerdrug #Rivoceranib #FDAapproval #livercancer #M&A #pharmaceuticalindustry